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Objective To assess the efﬁcacy and safety of clinaﬂoxacin as a single agent for the empi-
rical treatment of febrile episodes and bacterial infections in neutropenic cancer patients.
Methods An open label, active-controlled, randomized, parallel treatment, multicenter
study was conducted where clinaﬂoxacin monotherapy was compared to the combina-
tion of ceftazidime plus amikacin (plus optional vancomycin or teicoplanin). Four
hundred and nineteen patients were randomized to receive either intravenous clina-
ﬂoxacin 200mg every 12 h or intravenous ceftazidime (2 g) iv every 8 h plus intravenous
amikacin (15mg/kg) per day in divided doses. All randomized patients were to receive a
minimum of 48 h of primary study drug treatment, after which the primary treatment
could be modiﬁed. Clinical and microbiological responses were evaluated at 7–21 days
post-treatment after study treatment and long term (maximum 28days), in intent-to-treat
and modiﬁed intent-to-treat populations.
Results Clinaﬂoxacin and ceftazidime–amikacin were statistically equivalent for the 72-h
defervescence rate, overall defervescence rate, time to defervescence, clinical success
rate, by-pathogen microbiological eradication rate, and survival rate. Clinical cure was
achieved in 84% (59/70) of patients who received clinaﬂoxacin monotherapy. There were
no signiﬁcant differences between treatments in rates of adverse events or treatment
discontinuation rates due to adverse events.
Conclusions Clinaﬂoxacin appears to be an appropriate agent for empirical treatment in
febrile neutropenic cancer patients.
Keywords Febrile neutropenia, clinaﬂoxacin, ceftazidimine, amikacin, cancer patients,
monotherapy
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INTRODUCTION
Fever is often indicative of infection in neutro-
penic cancer patients. Sixty percent of patients
with chemotherapy-induced neutropenia develop
infection-related or unexplained fevers, and 20%
of those with profound neutropenia (neutrophil
count <100/mL) have bacteremia [1]. Bacterial
infections in this population carry high rates of
morbidity and mortality. Therefore, prompt
empirical antibiotic therapy is critical, since infec-
tions can be fatal within 48–72 h [2].
Aerobic Gram-negative (e.g. Escherichia coli,
Klebsiella pneumoniae and Pseudomonas aeruginosa)
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and Gram-positive (e.g. Staphylococcus aureus, co-
agulase-negative staphylococci, Streptococcus pneu-
moniae and viridans group streptococci) bacteria
are common pathogens in febrile neutropenic
patients [1,3,4]. With the use of indwelling intra-
vascular devices and the use of prophylaxis for
Gram-negative bacterial infections, Gram-positive
organisms are progressively replacing Gram-
negative organisms as the most frequent cause
of more serious infections [5].
The use of wide-spectrum therapy has been
widely adopted as standard clinical practice in
the treatment of neutropenic patients with bacter-
ial infections. This often involves a combination of
antibacterials covering the whole range from
Gram-negative to -positive pathogens. A combina-
tion of an antipseudomonal b-lactam drug plus an
aminoglycoside is one of the best-established treat-
ment regimens for febrile neutropenia.
Clinaﬂoxacin (CI-960, PD 127391) is an ex-
tended-spectrum ﬂuoroquinolone that is being
investigated for the treatment of serious infections
[6,7]. In vitro studies show that clinaﬂoxacin is
active against Enterobacteriaceae, Gram-negative
non-Enterobacteriaceae, Gram-positive cocci, in-
cluding most ciproﬂoxacin-resistant S. aureus
strains, multiresistant bacteria, intracellular patho-
gens, and most strict anaerobes [8–10]. These in
vitro data suggest that clinaﬂoxacin may be effec-
tive as monotherapy in the treatment of infections
in febrile neutropenic cancer patients. The objec-
tive of this study was to assess the efﬁcacy and
safety of clinaﬂoxacin as a single agent for the
empirical treatment of febrile episodes and bacter-
ial infections in neutropenic cancer patients.
MATERIALS AND METHODS
Study participants
The study was conducted according to the
Declaration of Helsinki, and study procedures
were approved by an independent Ethical Com-
mittee for each site. All study patients provided
written informed consent.
Patients were hospitalized throughout the
length of the study, were 18 years of age, and
had cancer (solid tumors or hematologic malig-
nancies), chemotherapy-related neutropenia (for
an expected duration of 5days), and fever,
deﬁned as an oral or tympanic temperature of
38 8C on one occasion and in the absence of an
obvious non-infectious cause such as a blood
transfusion or cytotoxic drug administration. Neu-
tropenia was deﬁned as an absolute neutrophil
count of 500/mL, or >500/mL but 1000/mL and
expected to fall below 500/mL within 48 h of the
initiation of therapy.
Exclusion criteria included: septic shock, HIV
infection, unlikely resolution of granulocytopenia
within 4weeks (e.g. aplastic anemia), allogenic
bone marrow transplant, signiﬁcant risk or history
of seizure, <48-h life-expectancy, hemodialysis
treatment, treatment with antibacterial agents
(not including prophylactic non-quinolone anti-
biotics) within 7 days prior to randomization,
abnormal elevation of total bilirubin (3 times
the upper limit of normal), alanine aminotransfer-
ase, aspartate aminotransferase (5 times the
upper limit of normal) or prothrombin time
(1.5 times the upper limit of normal). After ran-
domization, concurrent use of antibacterial agents
other than those described above, immunoglobu-
lins, and monoclonal antibodies, growth factors
such as granulocyte colony-stimulating factor
(G-CSF), granulocyte–macrophage colony-stimu-
lating factor (GM-CSF) and licensed immunoglo-
bulins and hyperimmune antisera was prohibited.
Pregnant patients, breastfeeding patients or pa-
tients with pregnancy potentialwere also excluded
from the study.
Study design
This was an open label, active-controlled, rando-
mized, parallel treatment, multicenter study.
Patients were randomized to receive either intra-
venous clinaﬂoxacin (200mg) every 12h or intrave-
nous ceftazidime (2 g) iv every 8 hplus intravenous
amikacin 15mg/kg per day in divided doses
according to a randomization code prepared by
the Parke-Davis Biometrics Department. An inde-
pendent randomization schedule was prepared
for each study center. The planned treatment ratio
at each center was 1:1, and a block size of four
was used, with two treatment replicates per block.
For patients with renal dysfunction, dosing was
adjusted. Whenever a Gram-positive resistant
pathogen was identiﬁed or suspected, a glycopep-
tide antibiotic (e.g. vancomycin) could be added
or, in case of resistance, any other aminoglycoside
(e.g. tobramycin) could be substituted for amika-
cin, as appropriate. The use of a non-antibacterial
agent (e.g. antifungal, antiviral, antiparasitic) in
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either study arm was also allowed, if indicated.
Initial study drug therapy was maintained for a
minimum of 48 h.
A clinaﬂoxacin dose of 200mg every 12 h was
selected in order to maintain a peak plasma con-
centration of 2–4mg/L. This was expected to be
sufﬁcient against the majority of pathogens in
neutropenic patients. Drug doses were adjusted
in patients with impaired renal function (patients
with creatinine clearance <50mL and 10mL
received 100mg every 12 h; those with creatinine
clearance <10mL received 100mg every 24 h).
Infusion time was 60min for the studymedication.
All randomized patients were to receive a mini-
mum of 48 h of primary study drug treatment,
after which the primary treatment could be mod-
iﬁed if: fever persisted and clinical signs and
symptoms persisted or deteriorated; a baseline
pathogen persisted; a bacterial pathogenwas treat-
ment resistant; superinfection was documented; a
new infection site developed; or a non-bacterial
infection was identiﬁed or suspected. Protocol-
allowed modiﬁcations included the addition of a
glycopeptide antibiotic (e.g. vancomycin) for
drug-resistant Gram-positive pathogens, or sub-
stitution of another aminoglycoside (e.g. tobramy-
cin) for amikacin-resistant pathogens. Add-on
antibiotics were administered at manufacturer-
recommended doses.
If fever subsided after study treatment was
started, primary treatment was continued for at
least 5 days until the absolute neutrophil count
was 500/mL, or until resolution of a localized
infection. Patients with microbiologically docu-
mented infections received a minimum of 5days
of study medication. Patients with unexplained
fever were treated for a minimum of 72 h. If
patients remained febrile and neutropenic after
5 days of study treatment, they received concomi-
tant empirical antifungal treatment until they
became afebrile and neutropenia resolved.
Concomitant antifungal, antiviral or antipro-
tozoan medications were allowed if indicated, as
well as oral non-absorbable antimicrobial drugs
(e.g. vancomycin) for prophylaxis and for Clostri-
dium difﬁcile colitis.
Baseline screening procedures performed after
onset of fever within 48 h before initiation of study
drug treatment included:medical history, physical
examination, clinical assessment of signs and
symptoms (cough, dyspnea, abdominal rigidity,
abdominal pain, erythema at the presumed site of
infection, skinulceration, localized tenderness, and
rigors/chills), baseline culture collection,measure-
ment of body temperature, and clinical laboratory
tests (hematology, blood chemistry, urinalysis).
Clinical laboratory testing and physical examina-
tion were performed at study admission and were
repeated on days 4, 10, 17 and 24 during treatment,
at the end of treatment, and at follow-up, 7–21days
post-therapy. Clinical signs and symptoms were
assessed after 72 h of study drug treatment, on
days 4, 10, 17 and 24, at the end of treatment, and at
follow-up. Patients were closely monitored on a
daily basis by the investigators.
Baseline cultures were collected from blood and
appropriate body sites and were repeated during
therapy as long as they were positive, and at
follow-up. All suspected pathogens were identi-
ﬁed and tested for susceptibility to clinaﬂoxacin,
ceftazidime, and amikacin. Clinaﬂoxacin mini-
mum inhibitory concentrations (MICs) were deter-
mined using the Etest methodology, and zones
using Kirby–Bauer disk diffusion methods. Patho-
gens were also sent to a central laboratory (GR
Micro Limited, London, UK) for identiﬁcation and
susceptibility testing. At the central laboratory,
MICs for clinaﬂoxacin and all potential add-on
antibiotics were determined by broth microdilu-
tion, and zones by Kirby–Bauer disk diffusion.
Testing procedures and susceptibility interpreta-
tions used by the central laboratory conformed
with National Committee for Clinical Laboratory
Standards (NCCLS) guidelines [11]. Susceptibility
breakpoints for clinaﬂoxacin are as follows: sus-
ceptible 1mg/L (21mm), intermediate 2mg/L
(18–20mm), and resistant4mg/L (17mm) [11].
Patient populations for analysis
The intent-to-treat population (all patients rando-
mized to treatment) was the primary analysis
population for clinical response. In addition, the
following patient populations were included for
efﬁcacy analysis: the modiﬁed intent-to-treat
population (had correct diagnosis, a documented
infection, a proven pathogen at baseline, a follow-
up blood culture, and received at least one dose
of primary study drug); the clinically assessable
population (had correct diagnosis, a documented
infection, and at least one sign or symptom at
baseline; received study medication as prescribed;
did not receive prior antibacterial agents; had
clinical assessmentsperformedwithin the speciﬁed
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study window); and the microbiologically assess-
able population (had proven baseline pathogen
that was susceptible to each study drug regimen,
and had microbiological assessments performed
within the range of days speciﬁed by protocol—
includes patients who had microbiological and/or
clinical assessments before the follow-up visit
window or who received concurrent antibacterial
treatment because they were early treatment fail-
ures). Data from various subpopulations were also
analyzed: patients with fever of unknown origin
(FUO); patients with bacteremia; patients with
bacteremia but no local infection; and all patients
with infection. All randomized patients who
received at least one dose of study drug were
included in the safety analyses. Survival data were
periodically analyzed by an Independent Safety
Monitoring Board.
Assessment of efficacy
The following criteria for the assessment of
responses to study drugwere used. For the clinical
success rate, the investigator’s assessment of clin-
ical effectiveness was used for those patients hav-
ing an assessment. Patients with unexplained FUO
or bacteremia without source were considered ‘not
assessable’ by the investigator, as stipulated in the
protocol. For these patients, the following assess-
ment was made by the sponsor: if the patient
survived and defervesced at any time during the
treatment and follow-up period, the patient was
considered a success; otherwise, the patient was
considered a failure. The intent-to-treat population
was used for all summaries. This population was
further broken down according to treatment mod-
iﬁcation (none, allowed, non-allowed, any), source
of infection (bacteremia, local infection), and
whether those with local infection had positive
or negative site cultures.
For failure, the criteria were either: death due to
baseline infection after survival for 48 h; no sig-
niﬁcant remission of clinical signs and symptoms
during treatment; remission followed by reappear-
ance of initial signs and symptoms during follow-
up period; patient not assessable because of
incomplete data; patient received a protocol-
allowed add-on antibacterial agent before com-
pleting 48 h of primary study drug treatment or
more than one dose of a non-allowed antibacterial
agent; or patient assessed as a failure at any pre-
vious visit.
The patient was considered to be not assess-
able if the investigator was unable to assess the
patient.
The minimum durations of therapy with study
drug required for eligibility as success or failure
were 72 h for patients with FUO and 5days for
those with documented infection. Patients who
became febrile and required concomitant non-anti-
bacterial therapy (e.g. antiviral, antiparasitic, anti-
fungal) were considered as not assessable in the
analyses.
Primary efficacy parameters
Primary efﬁcacy parameters were defervescence
rate at 72 h (percentage of patients who were afeb-
rile (i.e. maximumbody temperature<38 8C)with-
in 72 12 h after the ﬁrst dose of study drug),
overall defervescence rate (percentage of patients
who became afebrile (maximumbody temperature
<38 8C) for a 24-h period and through to the end of
treatment), clinical success rate, and microbiolog-
ical eradication rate by patient and by pathogen.
Microbiological eradication rate by pathogen was
calculated as the percentage of baseline pathogens
eradicated (actual plus presumed) from the follow-
up cultures of the baseline infection site and blood
in patientswhodid not receive non-allowed agents
for their baseline infection. Pathogens were pre-
sumed to be eradicated if there were no follow-up
cultures, and the patient was assessed as a clinical
cure. Pathogens were considered persistent if the
baseline pathogen was present in the follow-up
culture of the baseline infection site or blood,
and presumed persistent if culture data from the
baseline infection site or blood cultureswere absent
and the patient was assessed as a clinical failure or
not assessable, or a patient received non-allowed
agents. A ‘true’ microbiological response, deﬁned
as negative follow-up cultures, regardless of
the use of non-allowed agents, was also deter-
mined in order to account for the possibility that
categorization of ‘presumed persistence’ because
of the use of non-allowed agents could mask true
eradication.
The survival rate was deﬁned as percentage
of patients who survived until the test of cure
visit, 7–21 days post-therapy.
Secondary efficacy parameters
Secondary efﬁcacy parameters were: time to
defervescence (i.e. number of days from the ﬁrst
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dose of study drug to ﬁrst detection of body
temperature <38 8C during a 24-h period), sur-
vival rate–cause of death, baseline pathogen resis-
tance, development of resistance, superinfection
rate, reinfection rate, relapse (isolation of at least
one baseline pathogen between the end of treat-
ment and follow-up) rate, and time to treatment
modiﬁcation. Superinfection was deﬁned as the
isolation from the same baseline infection site
and/or blood of a non-baseline pathogen be-
tween day 2 and end of treatment. Reinfection
was deﬁned as the isolation from the same base-
line infection site of a non-baseline pathogen after
the end of study drug treatment. Suspected
or documented fungal infections were also
evaluated.
Assessment of safety
Safety was assessed according to adverse events,
physical examination, deaths, and abnormal
changes in clinical laboratory test results. Adverse
events were deﬁned, as per ICH-GCP Guidelines,
as any untoward medical occurrence observed in
or reported by a patient who is participating in a
clinical trial, regardless of whether or not it is
considered to be drug related. The investigator
evaluated the relationship of adverse events with
study drug, intensity (mild, moderate, severe), and
clinical course (e.g. outcome).
Statistical analysis
The hypothesis tested in this study was that
clinaﬂoxacin monotherapy is equivalent to cefta-
zidime plus amikacin, as a single agent, for the
empirical treatment of febrile hospitalized adult
neutropenic cancer patients. An overall clinical
success rate of 75% across randomized groups
was assumed in the sample size calculation, based
on results from a previous study with clinaﬂox-
acin. Equivalencewas to be assessed by comparing
a two-tailed 95% conﬁdence interval (CI) for the
difference in clinical success rates to upper and
lower bounds within 15% and 15%, respectively.
A sample size of 150 clinically assessable patients
per treatment group would be required to show
the equivalence of clinical success rates between
treatments in the clinically assessable population
with 90% power, using this CI method. All sum-
maries and analyses were generated using SAS
(Version 6) [12].
Treatment equivalence between clinaﬂoxacin
and ceftazidime–amikacin was tested for 72-h
and overall defervescence rate, clinical success
rate, and by-pathogen and by-patient microbiolo-
gical eradication rates using a prespeciﬁed equiva-
lence method. Unweighted point estimates for the
between-treatment differences in response rates
were obtained using a categorical modeling pro-
cedure [13]. For the above efﬁcacy parameters and
for survival rate, two-tailed 95% CIs were con-
structed about the differences in these parameter
estimates (clinaﬂoxacinminus ceftazidime–amika-
cin) using a standard normal approximation.
Treatment equivalence was evaluated by compar-
ing the resulting CI for each pairwise difference
with previously deﬁned ﬁxed criteria: if the 95%CI
did not contain zero, treatment was superior; if the
95%CI for treatment difference contained zero and
was within 10%, þ10% (for maximum response
90%), 15%, þ15% (for maximum response 80–
89%), and 20%, þ20% (for maximum response
<80%), the treatments were considered equiva-
lent. To support these conclusions, response rates
between treatments were analyzed using a
Cochran–Mantel–Haenszel method adjusting for
center and cancer type (hematologic or solid); the
Breslow–Day method was used at the 0.15 signiﬁ-
cance level to test for treatment-by-center or treat-
ment-by-cancer interaction.
Descriptive statistics were calculated for sec-
ondary efﬁcacy parameters. The Cochran–Mantel–
Haenszel analysis was used to test the association
between treatment group and baseline pathogen
resistance rates. Between-treatment difference for
time to defervescence was tested using survival
analysis methods [14]. Kaplan–Meier survival
function for time to defervescence was estimat-
ed for the treatment groups and graphically
displayed. Wald’s test statistic was used to deter-
mine between-treatment similarity. Overall ad-
verse event rates, drug-associated adverse event
rates and treatment discontinuation rates due to
adverse events were compared using a center-
adjusted Cochran–Mantel–Haenszel analysis.
An external, independent safety-monitoring
committee of medical, pharmaceutical and statis-
tical experts monitored all-cause mortality during
the study. Interim, blinded mortality analyses
occurred at enrollment levels of 112, 224 and 336
patients. The committee completed all three
reviews and sent notices of study continuation
to the sponsor on all three occasions.
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RESULTS
The study was performed at 16 sites in eight
different countries: Australia, Belgium, France,
Germany, Ireland, South Africa, Spain, and
Switzerland; 423 patients were recruited between
March 1995 and July 1997. Four patients entered
twice and insufﬁcient data were collected from
four patients. Efﬁcacy data from the ﬁrst course
of treatment were used in the analysis.
The intent-to-treat population included a total of
419 patients, 204 in the clinaﬂoxacin group and 215
in the ceftazidime–amikacin group. The demogra-
phics and baseline characteristics of each treatment
group were similar (Table 1). In both treatment
groups, there were more men than women, and
the majority were white, were <65 years of age,
had hematologic malignancies, and had a baseline
absolute neutrophil count of <100/mL. Of the total
of patients, 55% were bone marrow transplant
recipients, and 56% had FUO. The depth andmean
duration of neutropenia of patients from different
subpopulations are shown in Table 2. Only about
10% of patients exhibited signs and symptoms of
infection, most commonly localized as tenderness
(11.8%), rigor/chills (10.8%), abdominal pain
(8.9%), and cough (8.8%). Clinaﬂoxacin-treated
patients experienced more mild localized tender-
ness (7.8%) and moderate abdominal pain (5.4%)
than ceftazidime–amikacin-treated patients (2.8%
and 1.9%, respectively).
For the ITT population and patients who com-
pleted the planned treatment (primary study drug
plus protocol-allowed add-ons), the median expo-
sures were 8 days for clinaﬂoxacin and 9days
for ceftazidime–amikacin. Overall, approximately
one-third of all patients in each treatment group
received a protocol-allowed add-on concurrently.
In the clinaﬂoxacin group, 69 patients (33.8%)
received concurrent vancomycin, seven (3.4%)
teicoplanin, and one (0.5%) tobramycin. In the
ceftazidime–amikacin group, 80 patients (37.2%)
received vancomycin and 12 (5.6%) teicoplanin.
No patients in the ceftazidime–amikacin group
received tobramycin as add-on therapy. Approxi-
mately 50%of the patients received antiviral agents
(acyclovir), and 73% received antifungal treatment
(most commonly amphotericin B or ﬂuconazole).
Of the 419 intent-to-treat patients, 417 received the
study drug (two patients did not receive ceftazi-
dime–amikacin), 268 (64%) completed treatment,
and 404 (96%) completed the follow-up visit. Clin-
aﬂoxacin was discontinued prematurely in 81 pa-
tients (40%) and ceftazidime–amikacin in 68 (32%)
patients, the main reasons being treatment fail-
ure and adverse events (Table 3). The distribution
of patients in the clinaﬂoxacin and ceftazidime–
amikacin groups in the modiﬁed intent-to-treat
(n¼ 71, n¼ 70, respectively), clinically evaluable
(n¼ 65, n¼ 57, respectively) and microbiologically
evaluable (n¼ 48, n¼ 42, respectively) populations
Table 1 Patient characteristics at baseline in the intent-to-
treat population (number (%) of patients)
Clinafloxacin
(n¼ 204)
Ceftazidime–
Amikacin
(n¼ 215)
Sex
Male 112 (55) 122 (57)
Female 92 (45) 93 (43)
<50 years 52 (57) 52 (56)
50 years 40 (43) 41 (44)
Race
White 198 (97) 205 (95)
Othera 6 (3) 10 (5)
Age (years)
Median (range) 45 (18–75) 45 (19–74)
<65 191 (94) 200 (93)
65 13 (6) 15 (7)
Etiology of fever
Unexplained fever 112 (55) 121 (56)
Bacteremia of
unknown source
51 (25) 53 (25)
Local infection 23 (11) 32 (15)
Bacteremia of
Known source
17 (8) 9 (4)
Unknown 1 (0.5) 0 (0)
Baseline absolute
neutrophil count
<100/mL 135 (66) 143 (66)
100–500/mL 61 (30) 64 (30)
>500/mLb 9 (4) 8 (4)
Tumor type and
bone marrow
transplant
(BMT) status
Solid tumorc 29 (14) 42 (19)
Autologous BMT 19 (66) 28 (67)
No BMT 10 (34) 14 (33)
Hematologic
malignancyd
175 (86) 173 (81)
Autologous BMT 94 (54) 89 (51)
No BMT 81 (46) 84 (49)
Received growth
factors
118 (58) 133 (62)
aIncludes blacks, Asians and other.
bPatients whose baseline absolute neutrophil count was
expected to drop to <500/mL was unknown.
cPrimarily breast and sarcoma.
dPrimarily non-Hodgkin’s lymphoma.
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was similar to that of the intent-to-treat popula-
tion. Clinaﬂoxacin- and ceftazidime–amikacin-
treated patients were excluded from clinical eva-
luability mainly because of FUO (55% and 56%,
respectively), and insufﬁcient treatment duration
(12% and 7%, respectively), and from modiﬁed
intent-to-treat (65% and 66%, respectively) and
microbiological assessability (65% and 66%, re-
spectively) because of a lack of a proven baseline
pathogen.
Baseline pathogens
In total, 194 pathogens were identiﬁed in the
modiﬁed intent-to-treat population at baseline.
Single Gram-positive pathogens from blood or
local foci were the most common baseline isolates
(in 58/141 (41%) patients). Staphylococcus epidermi-
dis, isolated in 13 (18%) clinaﬂoxacin- and six (9%)
ceftazidime–amikacin-treated patients, and E. coli,
isolated, respectively, in seven (10%) and 11 (16%)
patients, were the most common pathogens. Sig-
niﬁcantly more baseline pathogens were resistant
to ceftazidime (P¼ 0.001) and amikacin (P¼ 0.001)
than to clinaﬂoxacin (Table 4). Pathogens isolated
from blood are listed in Table 5.
Efficacy
Primary efficacy parameters
The effects of study drug treatment in the intent-
to-treat population and related subpopulations on
defervescence and clinical success rate are sum-
marized in Table 6. Defervescence rates at 72 h and
overall were equivalent for clinaﬂoxacin- and cef-
tazidime–amikacin-treated patients in the intent-
Table 2 Depth and mean duration of neutropenia by tumor type and bone marrow transplant status in intent-to-treat
patients
Clinafloxacin
200mg every 12h
Ceftazidime-Amikacin
2 g every 8 h to 15mg/kg per day
Tumor type/
bone marrow transplant status Mean days n Mean days n
Solid
With bone marrow transplant n¼ 19 n¼ 28
ANC< 100 6 9 6 17
ANC< 500 8 19 7 27
Without bone marrow transplant n¼ 10 n¼ 14
ANC< 100 7 8 6 9
ANC< 500 6 9 6 13
Hematologic
With bone marrow transplant n¼ 94 n¼ 89
ANC< 100 8 84 8 76
ANC< 500 8 93 9 88
Without bone marrow transplant n¼ 81 n¼ 84
ANC< 100 8 67 9 78
ANC< 500 9 80 11 84
Table 3 Number of patients completing study treatment and reasons for discontinuing study drug treatment
Clinafloxacin (n (%)) Ceftazidime–Amikacin (n (%))
Total randomized to treatment 204 215
Completed study treatment 123 (60) 145 (67)
Total discontinuing treatment 81 (40) 68 (32)
Protocol non-compliance 6 (3) 3 (1)
Treatment failure 37 (18) 31 (14)
Death 2 (1) 3 (1)
Adverse event 25 (12) 21 (10)
Resistant baseline pathogen 5 (3) 2 (1)
Other/Administrative 6 (3) 8 (4)
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to-treat patient population and in patients with
FUO. The 72-h defervescence rate was higher in
patients who received unmodiﬁed clinaﬂoxacin
and clinaﬂoxacin plus protocol-allowed add-ons,
but lower for patients with documented infections.
The Kaplan–Meier median time to deferves-
cence was 6 days for intent-to-treat patients in both
treatment groups (Figure 1; 95% CI for risk ratio:
0.662, 1.09; P¼ 0.2).
Although there was a trend to a higher clinical
success rate at test of cure for the ceftazidime
regimen, both treatments were equivalent for clin-
ical success in the intent-to-treat patients and in
patients with FUO. Rates were similar for clina-
ﬂoxacin in the unmodiﬁed clinaﬂoxacin (97% ver-
sus 94%) subpopulation.
In the modiﬁed intent-to-treat population, by-
pathogen microbiological eradication (actual plus
presumed) rates were equivalent (95% CI 9.8%,
17.5%; P¼ 0.5) for clinaﬂoxacin (40/100, 40%) and
ceftazidime–amikacin (34/94, 36%). True eradica-
tion occurred in 67 of 67 (100%) of pathogens in
clinaﬂoxacin-treated and in 50 of 50 (100%) patho-
gens in ceftazidime–amikacin-treated patients.
Secondary efficacy parameters
Survival rate–cause of death Three clinaﬂoxacin-
and six ceftazidime–amikacin-treated patients
died while in the study. The causes of death in
the clinaﬂoxacin-treated patients were baseline
infection (fungal infection, pneumonia; n¼ 1),
adverse event (liver damage; n¼ 1), and unknown
(sudden death; n¼ 1), and in ceftazidime–amika-
cin-treated patients, baseline infection (septicemia;
n¼ 2), and adverse event (pulmonary aspergillo-
sis, septic shock (2), bronchopneumonia; n¼ 4)
(Table 7). None of the deaths was related to the
study drug. Survival rates were equivalent for
patients with FUO (98% CI 1.9, 6.7; P¼ 0.22),
patients with bacteremia (98% CI 6.8, 7.4;
P¼ 0.57), and all patients with infection (98% CI
4.1, 4.9; P¼ 0.94). The survival rate in patients
with bacteremia but no local infection was similar
for ceftazidime–amikacin (100% versus 96% for
clinaﬂoxacin; 98% CI 10.3, 2.5; P¼ 0.26).
Resistance/superinfection/reinfection Eight clina-
ﬂoxacin- and four ceftazidime–amikacin-treated
intent-to-treat patients had superinfecting patho-
gens, most commonly Gram-positive aerobes:
Enterococcus faecium, S. epidermidis and S. hominis
in the clinaﬂoxacin group, and S. epidermidis, Enter-
ococcus faecalis, and S. aureus in the ceftazidime–
amikacin group. One ceftazidime–amikacin-trea-
ted patient had Bacteroides fragilis superinfection.
Five clinaﬂoxacin-treated patients were superin-
Table 4 In vitro antibacterial activity of clinafloxacin and ceftazidime–amikacin for baseline pathogens (10 isolates) taken
from modified intent-to-treat patients
Clinafloxacin Ceftazidime–Amikacin
Pathogen n MIC range MIC50 MIC90 n MIC range MIC50 MIC90
Gram-positive
S. aureus 13 0.008–1.00 0.015 0.13 Ceftazidime¼ 12
Amikacin¼ 12
8–16
2–8
16.0
2.0
16.0
2.0
S. epidermidis 45 0.008–0.50 0.03 0.25 Ceftazidime¼ 38
Amikacin¼ 40
1–32
2–32
8.0
2.0
32.0
4.0
S. mitis 14 0.06–0.13 0.12 0.12 Ceftazidime¼ 13
Amikacin¼ 13
1–4
8–128
1.0
16.0
4.0
32.0
Gram-negative
E. coli 30 0.004–0.06 0.008 0.008 Ceftazidime¼ 28
Amikacin¼ 28
1–8
2–8
1.0
2.0
1.0
4.0
Table 5 Distribution of patients by baseline pathogens;
blood-borne pathogens (listed n 4)
Pathogen
Clinafloxacin
n¼ 71
Ceftazidime–
Amikacin
n¼ 70
Gram-positive
S. epidermidis 23 13
S. capitis 3 1
S. mitis 6 6
Gram-negative
E. coli 6 15
K. pneumoniae 5 1
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fected with multiple pathogens. One ceftazi-
dime–amikacin-treated patient had a reinfecting
pathogen (coagulase-negative Staphylococcus). All
superinfecting pathogens were susceptible or
intermediately susceptible to clinaﬂoxacin (17/17
isolates). In the ceftazidime–amikacin group, the B.
fragilis isolate was resistant to ceftazidime, and the
S. epidermidis isolate was resistant to amikacin; the
susceptibilities of the Enterobacter faecalis isolate
and the reinfecting coagulase-negative Staphylococ-
cus were unknown. Eight clinaﬂoxacin- and nine
ceftazidime–amikacin-treated patients developed
fungal infections, most commonly Candida species.
No pathogens developed drug resistance dur-
ing the course of study treatment.
The median time to any antibacterial treatment
modiﬁcation was 3days in both treatment groups
(1–17 days in the clinaﬂoxacin versus 1–14 days in
the ceftazidime group) (intent-to-treat population).
The median time to non-allowed antibacterial
Table 6 Effects of intravenous treatment with clinafloxacin 200mg every 12 h (n¼ 204) and ceftazidime (2 g every 8 h) plus
amikacin (15mg/kg per day) (n¼ 215) on primary clinical efficacy parameters in the intent-to-treat population and related
subpopulations
Efficacy parameter
Clinafloxacin
(n/N (%))
Ceftazidime–Amikacin
(n/N (%)) 95% CI P-valuea
Defervescence
rate at 72 h
All patients 76/204 (37) 86/215 (40) (12.1, 6.6) 0.60
Patients with FUO 53/112 (47) 47/121 (39) (4.2, 21,2) 0.44
Patients with bacteremia
(42.5, 10.4)
16/68 (24)
0.01
31/62 (50)
All patients with infection 23/91 (25) 39/94 (42) (29.6, 2.8) 0.05
Unmodified treatment 41/70 (59) 38/78 (49) – –
Protocol-allowed add-on 17/39 (44) 11/35 (31) – –
Overall defervescence rate
All patients 132/204 (65) 152/215 (71) (14.9, 3.0) 0.20
Patients with FUO 77/112 (69) 87/121 (72) (14.9, 8.6) 0.47
Patients with bacteremia 41/68 (60) 44/62 (71) (26.9, 5.5) 0.58
All patients with infection 55/91 (60) 65/94 (69) (22.4, 5.0) 0.42
Unmodified treatment 58/70 (83) 61/78 (78) – –
Protocol-allowed add-on 35/39 (90) 32/35 (91) – –
Clinical success rate
All patients 154/204 (76) 178/215 (83) (18.5, 1.6) 0.07
Patients with FUO 56/112 (50) 61/121 (50) (13.3, 12.4) 0.82
Patients with bacteremiab 13/13 (100) 17/18 (94) – –
Patients with infectionb 2/2 (100) 4/4 (100) – –
Unmodified treatment 67/69 (97) 72/77 (94) – –
Protocol-allowed add-on 37/39 (95) 35/35 (100) – –
Protocol-non-allowed add-on 50/95 (53) 71/102) (70) – –
n/N, number of patients who became afebrile at 72 h/total number of patients (in each subpopulation).
FUO, fever of unknown origin.
aP-value determined by Cochran–Mantel–Haenszel analysis, adjusting for center and cancer type.
bSubpopulation of patients without modifications.
Figure 1 Kaplan–Meir plot of time to defervescence for the
intent-to-treat population following intravenous treatment
with either clinafloxacin 200mg every 12 h (n¼ 204) or
ceftazidime 2 g every 8 h plus amikacin 15mg/kg per day
(n¼ 215). Wald P-value¼ 0.199, risk ratio¼ 0.849; 95% CI
for risk ratio¼ 0.662, 1.090. Kaplan–Meier medians: clin-
afloxacin¼ 6, ceftazidime–amikacin¼ 6.
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treatment modiﬁcation was 6 days for clinaﬂoxa-
cin- and 7days (1–21 days in both groups) for
ceftazidime–amikacin-treated patients.
Safety
In total, 207 patients in the clinaﬂoxacin group and
216 in the ceftazidime–amikacin group were eval-
uated for safety (one patient did not get the study
medication). Similar numbers/percentages of clin-
aﬂoxacin-treated (n¼ 162, 79%) and ceftazidime–
amikacin-treated (n¼ 169, 79%) patients (P¼ 0.89)
reported at least one adverse event. Discontinua-
tion rates due to adverse events were similar
(clinaﬂoxacin 12%; ceftazidime–amikacin 10%;
P¼ 0.50). Rash (n¼ 5), chills (n¼ 3) and pneumo-
nia (n¼ 3) were the most frequent reasons for
discontinuing clinaﬂoxacin, and rash (n¼ 8), infec-
tion (n¼ 2) and pneumonia (n¼ 2) for discontinu-
ing ceftazidime–amikacin. Thirteen (6.3%) and 10
(4.7%) cases of discontinuation of clinaﬂoxacin
and ceftazidime–amikacin, respectively, were for
drug-associated adverse events. Other adverse
events that led to clinaﬂoxacin withdrawal were
photosensitivity (n¼ 1), decreased blood glucose
(<2.8mmol/L, <50mg/dL) or hypoglycemia
(n¼ 2), and convulsion (n¼ 1).
Drug-associated adverse event rates were 28.3%
(n¼ 58) with clinaﬂoxacin and 23.0% (n¼ 49) with
ceftazidime–amikacin (P¼ 0.19). Diarrhea (clina-
ﬂoxacin 4.9%; ceftazidime–amikacin 6.1%) and
rash (clinaﬂoxacin 5.4%; ceftazidime–amikacin
7.0%) were the most frequent drug-associated
adverse events. Eight clinaﬂoxacin- and 10 cefta-
zidime–amikacin-treated patients were treated for
C. difﬁcile-associated diarrhea; three of six clina-
ﬂoxacin- and six of six ceftazidime–amikacin-trea-
ted patients tested for C. difﬁcile had conﬁrmed
toxin or culture results. Ceftazidime–amikacin
was associated with one documented case of pseu-
domembraneous colitis.
Three clinaﬂoxacin- and six ceftazidime–amika-
cin-treated patients died due to an adverse event
during the whole period of the study, including
baseline cancer. However, none of these deaths in
either group were considered to be related to a
study drug. One of the deaths in the clinaﬂoxacin
group and two from the ceftazidime group were
considered to be baseline infection related, and
included fatal bacteremia, septicemia, or septic
shock.
Approximately 90% of the patients in each treat-
ment group had markedly abnormal hematology,
blood chemistry and urinalysis laboratory values
at follow-up, compared to baseline. The most
marked abnormalities were decreases in white
blood cells, hemoglobin, and platelets, which were
expected as a result of recent chemotherapy and/
or underlying cancer.
DISCUSSION
This study demonstrated that empirical treatment
with clinaﬂoxacin (200mg IV every 12 h) is as effec-
tive as ceftazidime (2 g IV every 8 h) plus amikacin
(15mg/kg per day) in the initial treatment of
febrile episodes in neutropenic cancer patients.
The defervescence rate at 72 h was equivalent
for the overall intent-to-treat population; however,
rates in patients with bacteremia with or without
Table 7 Effects of intravenous treatment with clinafloxacin 200mg every 12 h (n¼ 204) and ceftazidime (2 g every 8 h) plus
amikacin (15mg/kg per day) (n¼ 215) on survival rate in the intent-to-treat population and related subpopulations
Efficacy parameter
Clinafloxacin
(n/N (%))
Ceftazidime–Amikacin
(n/N (%)) 98% CI P-valuea
All patientsb
(2.0, 4.8)
201/204 (98.5)
0.38
209/215 (97.2)
Patients with FUO
( 1.9, 6.7)
111/112 (99.1)
0.22
117/121 (96.7)
Patients with bacteremia
( 6.8, 7.4)
66/68 (97.1)
0.57
60/62 (96.8)
All patients with infection 89/91 (97.8) 92/94 (97.9) ( 5.1, 4.9) 0.94
n/N, number of patients who survived/total number of patients (in each subpopulation).
FUO, fever of unknown origin.
aP-value determined by Cochran–Mantel–Haenszel analysis adjusting for center and cancer type.
bOne clinafloxacin-treated patient had unknown fever etiology and was not included in the intent-to-treat subpopulation
analyses.
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local infection and in patients with infection
indicated ceftazidime–amikacin as the preferable
therapy. In FUO patients, the rates were higher
with clinaﬂoxacin but indicated neither equiva-
lence nor superiority.
The relatively low clinical success rates seen
with both clinaﬂoxacin and ceftazidime–amikacin
resulted from the strict criteria used to assess
patients. For example, investigators were instruc-
ted to assess patients as ‘clinically not assessable’ if
they had FUO or bacteremia with no known
source. The inclusion of non-assessable patients
in the denominator in the success rate calculation
lowered the overall success rate. The number of
failures was high because: (1) many patients were
classiﬁed as failures because they received proto-
col-allowed antibacterial add-on drugs within 48 h
of starting primary study drug or a non-allowed
antibacterial agent before follow-up; and (2) clin-
ical failures at the end of treatment were automa-
tically considered failures at follow-up.
Low clinical response rates (i.e. according to
the Immunocompromised Host Society guide-
lines) were observed in two other recently pub-
lished comparative studies that used strict
assessment criteria for febrile neutropenic cancer
patients [15–17]. The ﬁrst study reported clinical
success rates of 44% for meropenem and 41% for
ceftazidime [15], which are similar to the success
rates observed in our study (clinaﬂoxacin 44%,
ceftazidime–amikacin 43%). The second study
reported success rates of 56% with meropenem
and 52% with ceftazidime–amikacin [16]. These
studies employed similar rigorous deﬁnitions of
success.
Although this study demonstrated equivalence
for clinaﬂoxacin and ceftazidime–amikacin for
various efﬁcacy parameters, the primary objective
of this study, e.g. the evaluation of clinaﬂoxacin
monotherapy versus ceftazidime–amikacin for an
entire course of empirical treatment of febrile
neutropenic cancer patients, was not fully met.
Because of the serious illness of the study patients,
many investigators did not maintain the protocol-
speciﬁed course of study therapy for the ﬁrst 48 h
of treatment. This compromised the ability of this
study to fully evaluate clinaﬂoxacin as monother-
apy. Nonetheless, clinical cure was achieved in 59
of 70 (84%) patients who received clinaﬂoxacin
alone (i.e. unmodiﬁed study treatment) as com-
pared with 62 of 78 (80%) with unmodiﬁed
ceftazidime–amikacin treatment. The study did,
however, demonstrate that initial empirical mono-
therapywith clinaﬂoxacin was equivalent to initial
empirical therapy with ceftazidime–amikacin.
The safety proﬁles were similar and there were
no statistically signiﬁcant differences between
clinaﬂoxacin and ceftazidime–amikacin in rates
of adverse events, drug-associated adverse events,
or treatment discontinuation due to adverse events.
Adverse events associated with ﬂuoroquinolones
as a class effect, i.e. phototoxicity and convul-
sion, occurred rarely with clinaﬂoxacin. Decreased
blood glucose also occurred rarely.
CONCLUSIONS
The clinical efﬁcacies of clinaﬂoxacin and ceftazi-
dime–amikacin are equivalent in terms of 72-h and
overall defervescence rates, time to defervescence,
clinical success rate, by-pathogen microbiological
eradication rate, and survival rate in febrile, neu-
tropenic, intent-to-treat cancer patients. The safety
proﬁle of clinaﬂoxacin is similar to that for cefta-
zidime–amikacin and is clinically acceptable. The
study data support clinaﬂoxacin as appropriate
initial empirical treatment of cancer patients with
febrile neutropenia.
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